Navigation Links
Endologix Responds to Alleged Patent Infringement
Date:10/13/2009

IRVINE, Calif., Oct. 13 /PRNewswire-FirstCall/ -- Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today that it has conducted further evaluation of the patent infringement lawsuit filed against the company last week by Cook Medical, and of the patents asserted in the lawsuit. Based upon this evaluation, Endologix believes that the alleged infringement is without merit and the company intends to vigorously defend its position.

John McDermott, Endologix President and Chief Executive Officer, said, "We are pleased that our initial evaluation of these claims, which Cook Medical waited for years to assert, has already yielded support for numerous promising defenses."

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's flagship product is the Powerlink® System, which is an endovascular stent graft for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. Additional information can be found on Endologix's Web site at www.endologix.com

Forward-Looking Statements

Except for historical information contained herein, this news release contains forward-looking statements, specifically related to the claims of alleged infringement. Please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and the Company's other filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.

    COMPANY CONTACT:                           INVESTOR CONTACTS:
    ----------------                           ------------------
    Endologix, Inc.                            The Ruth Group
    John McDermott, CEO                        Nick Laudico (646) 536-7030
    (949) 595-7200                             Zack Kubow (646) 536-7020
    www.endologix.com

SOURCE Endologix, Inc.


'/>"/>
SOURCE Endologix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Endologix Comments on Alleged Patent Infringement
2. EPSScentral Responds to Pandemic Alert
3. AstraZeneca Responds to FDA Joint Advisory Committees Recommendation on SYMBICORT(R)
4. GSK Believes There Is No Liver Safety Issue With AVANDIA; Responds to Public Citizen Petition
5. GlaxoSmithKline Responds to FDA on CERVARIX(R) and Plans to Submit Final Study Data for Approval
6. Roche responds to announcement of IDEAL hepatitis C trial results
7. Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
8. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
9. GlaxoSmithKline and U.S. Patent and Trademark Office File a Motion to Dismiss Litigation Over Final Regulations
10. Caraco Pharmaceutical Laboratories, Ltd. Closes Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation
11. Biostar Pharmaceuticals, Inc. Receives Patent for Aoxing Ganbao
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... May 5, 2016  Diagnostic imaging has been ... to concerns that these tests cause health care costs to ... imaging, as well as the adoption of new ... medical peripherals that help health care providers cut costs, while ... medical imaging is a renowned authorized reseller of the ...
(Date:5/5/2016)... 5, 2016 Research ... "Europe Thalassaemia Market and Competitive Landscape Highlights ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) ... and Competitive Landscape Highlights - 2016, provides ... epidemiology, Thalassaemia market valuations and forecast, Thalassaemia ...
(Date:5/4/2016)... NESS ZIONA, Israel , May ... BVXV, TASE: BVXV) announced today that BiondVax,s CEO, Dr. ... 2016 conference in New York City . ... presenting at 10:30am at Pioneers 2016, a conference presented by ... New York Palace Hotel. The BiondVax presentation that ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... ... Overseer at The House of Yahweh, has written a new article this week meant to ... stop cancer. Yisrayl says there are too many suffering and dying from the disease to ... pay close attention and take action. The Pastor says that the root cause of all ...
(Date:5/6/2016)... MOOREFIELD, W.V. (PRWEB) , ... May 06, 2016 , ... ... by WestBow Press) shares accounts of dying patients who have allowed those holding vigil ... June E. Kuykendall, RN, BSN, CHPN, hopes to help readers spiritually and practically gain ...
(Date:5/5/2016)... PA (PRWEB) , ... May 05, 2016 , ... ... on long-acting injectables (LAIs), today announced a development collaboration with the ... to treat serious mental disorders such as schizophrenia. , LAI medicines can offer ...
(Date:5/5/2016)... ... May 05, 2016 , ... TLC Laser Eye Centers announced today that ... eye center will now be called “Gordon Schanzlin New Vision Institute, a TLC Laser ... the full-service facility to ensure that patients continue to receive the highest quality of ...
(Date:5/5/2016)... ... 2016 , ... LELO has discovered many people are insecure about ... via email, social media and on the Volonté blog seeking advice about how to ... ‘normal’ or ‘correct’?” , While some methods are more common than others, there is ...
Breaking Medicine News(10 mins):